- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06270706
Een fase 1-onderzoek naar PLN-101095 bij volwassenen met gevorderde of gemetastaseerde solide tumoren
Een fase 1a/1b multicenter, open-label dosisescalatie-/uitbreidingsonderzoek om de veiligheid, verdraagbaarheid, farmacokinetiek en voorlopig bewijs van antitumoractiviteit van PLN-101095 als monotherapie en in combinatie met pembrolizumab te evalueren bij volwassen deelnemers met gevorderde of gemetastaseerde solide tumoren Die ziekteprogressie hebben terwijl ze Pembrolizumab gebruiken
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.
The study will consist of 2 main parts:
- Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
- Part 2: Dose-expansion cohorts using Simon's 2-stage design
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Pliant Therapeutics Medical Monitor
- Telefoonnummer: clintrials@pliantrx.com
- E-mail: clintrials@pliantrx.com
Studie Locaties
-
-
Barcelona
-
Barcelona, Barcelona, Spanje, 08023
- Werving
- Hospital Universitari Quirónsalud (NEXT Barcelona)
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanje, 08023
- Werving
- START Barcelona - Hospital HM Nou Delfos
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spanje, 08035
- Werving
- Hospital Universitari Vall d'Hebron - VHIO
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
La Rioja
-
Logroño, La Rioja, Spanje, 26006
- Werving
- START Center for Cancer Research - La Rioja
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Madrid
-
Madrid, Madrid, Spanje, 28040
- Werving
- START Madrid - Hospital Universitario Fundación Jiménez Díaz
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Madrid, Madrid, Spanje, 28050
- Werving
- START Madrid - Centro Integral Oncológico Clara Campal
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Pozuelo de Alarcón
-
Madrid, Pozuelo de Alarcón, Spanje, 28223
- Werving
- University Hospital Quironsalud Madrid (NEXT Madrid)
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06511
- Voltooid
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20007
- Werving
- Georgetown University Medical Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Winship Cancer Institute of Emory University
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Michigan
-
Grand Rapids, Michigan, Verenigde Staten, 49546
- Werving
- South Texas Accelerated Research Therapeutics (START)
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University Medicine
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New Jersey
-
East Brunswick, New Jersey, Verenigde Staten, 08816
- Werving
- START New Jersey
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
New Brunswick, New Jersey, Verenigde Staten, 08901
- Werving
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
New York
-
Lake Success, New York, Verenigde Staten, 11042
- Werving
- START New York Long Island LLC
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
North Carolina
-
Wilson, North Carolina, Verenigde Staten, 27893
- Werving
- Carolina Cancer Research Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57105
- Werving
- Avera Medical Group
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Tennessee Oncology
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78758
- Werving
- NEXT Austin
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- START Center for Clinical Research
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- University of Texas MD Anderson Cancer Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Houston, Texas, Verenigde Staten, 77054
- Werving
- NEXT Houston
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- UT Health San Antonio's Mays Cancer Center
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Utah
-
West Valley City, Utah, Verenigde Staten, 84119
- Werving
- START Mountain Region
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- Inova Schar Cancer Institute
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- NEXT Virginia
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Washington
-
Edmonds, Washington, Verenigde Staten, 98026
- Werving
- Swedish Cancer Institute Medical Oncology
-
Contact:
- Pliant Therapeutics Medical Monitor
- E-mail: clintrials@pliantrx.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Has histologically or cytologically confirmed advanced or metastatic solid tumor
- Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
- Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
- Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
- At least 1 measurable lesion, as defined by RECIST v1.1
- Estimated survival of ≥3 months
- Have adequate bone marrow and organ function.
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria:
- Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
- Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
- Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known active CNS metastases (brain and/or leptomeningeal metastases)
- Has significant cardiac disease
- Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
- Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1 Dose Escalation - 250 mg BID
Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimenteel: Part 1 Dose Escalation - 500 mg BID
PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimenteel: Part 1 Dose Escalation - 1000 mg BID
PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimenteel: Part 1 Dose Escalation - 1000 mg TID
PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimenteel: Part 1 Dose Escalation - 2000 mg BID
PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimenteel: Part 2 Dose Expansion - NSCLC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimenteel: Part 2 Dose Expansion - ccRCC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Experimenteel: Part 2 Dose Expansion - TMB-high solid tumors
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tijdsspanne: First dose to 35 days
|
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications. |
First dose to 35 days
|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Tijdsspanne: Day 1 until 16 weeks after end of study treatment regimen
|
Proportion of participants with treatment-emergent adverse events and serious adverse events. |
Day 1 until 16 weeks after end of study treatment regimen
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tijdsspanne: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tijdsspanne: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tijdsspanne: Day 14, 0 to up to 12 hours
|
Maximum drug concentration (Cmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tijdsspanne: Day 14, 0 to up to 12 hours
|
Time to Cmax (Tmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Tijdsspanne: Day 14, 0 to up to 12 hours
|
Area under the concentration-time curve (AUC0-τ) |
Day 14, 0 to up to 12 hours
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tijdsspanne: First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
Duration of response (DOR) for objective responders |
First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Tijdsspanne: First dose to progression or death from any cause, whichever occurs first
|
Time on treatment (TOT) for objective responders |
First dose to progression or death from any cause, whichever occurs first
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Pliant Therapeutics Medical Monitor, Pliant Therapeutics, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Urotheelcarcinoom
- Immunotherapie
- Pembrolizumab
- Melanoma
- Colorectale kanker
- Endometriumkanker
- Niet-kleincellige longkanker (NSCLC)
- Cholangiocarcinoom
- Gevorderde solide tumoren Kanker
- Galblaas
- Ovariumcarcinoom
- Triple negatieve borstkanker (TNBC)
- Anale carcinoom
- Clear cel niercelcarcinoom (CCRCC)
- Galwegcarcinoom (BTC)
- Plaveiselcelcarcinoom van het hoofd en de hals (HNSCC)
- Tumor mutational burden (TMB)-hoge tumoren
- TMB-lage tumoren
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Endocriene systeemziekten
- Pathologische processen
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Darmziekten
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Intestinale neoplasmata
- Rectale ziekten
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Longziekten
- Endocriene klierneoplasmata
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Colon Ziekten
- Neoplastische processen
- Longneoplasmata
- Ovariële ziekten
- Adnexale ziekten
- Genitale neoplasmata, vrouwelijk
- Gonadale aandoeningen
- Huidziektes
- Borst ziekten
- Urologische neoplasmata
- Carcinoom
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Nierneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Baarmoeder Neoplasmata
- Neuro-endocriene tumoren
- Nevi en melanomen
- Huidneoplasmata
- Borstneoplasmata
- Anus Ziekten
- Rectale neoplasmata
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Colorectale neoplasmata
- Ovariumneoplasmata
- Neoplasma metastase
- Carcinoom, niercel
- Carcinoom, niet-kleincellige long
- Cholangiocarcinoom
- Melanoma
- Drievoudige negatieve borstneoplasmata
- Endometriumneoplasmata
- Carcinoom, overgangscel
- Anus Neoplasmata
- pembrolizumab
Andere studie-ID-nummers
- PLN-101095-ONC-101
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .